Envista (NYSE:NVST) Upgraded by Wall Street Zen to “Strong-Buy” Rating

Wall Street Zen upgraded shares of Envista (NYSE:NVST) from a buy rating to a strong-buy rating in a research report sent to investors on Saturday morning.

Several other brokerages have also recently commented on NVST. Piper Sandler reiterated a “neutral” rating and issued a $28.00 target price (up from $26.00) on shares of Envista in a report on Thursday, August 6th. Zacks Research raised shares of Envista from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 7th. Morgan Stanley set a $23.00 price target on shares of Envista in a report on Thursday, August 6th. Mizuho set a $29.00 price target on shares of Envista in a research report on Thursday, August 6th. Finally, Weiss Ratings raised shares of Envista from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, Envista currently has an average rating of “Moderate Buy” and an average target price of $29.31.

Envista Trading Up 1.0%

Shares of NYSE NVST opened at $27.21 on Friday. Envista has a 12 month low of $18.77 and a 12 month high of $30.42. The company has a market cap of $4.37 billion, a price-to-earnings ratio of 46.91, a P/E/G ratio of 1.30 and a beta of 0.86. The company has a quick ratio of 2.07, a current ratio of 2.43 and a debt-to-equity ratio of 0.47. The business has a fifty day simple moving average of $26.90 and a 200-day simple moving average of $26.28.

Envista (NYSE:NVST) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.07. The business had revenue of $730.50 million during the quarter, compared to analyst estimates of $716.11 million. Envista had a return on equity of 7.88% and a net margin of 3.33%.Envista’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same quarter last year, the company posted $0.26 EPS. Envista has set its FY 2026 guidance at 1.500-1.550 EPS. Sell-side analysts predict that Envista will post 1.53 EPS for the current year.

Institutional Investors Weigh In On Envista

A number of institutional investors have recently bought and sold shares of NVST. Dimensional Fund Advisors LP grew its stake in Envista by 1.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 9,780,948 shares of the company’s stock valued at $248,130,000 after acquiring an additional 152,488 shares in the last quarter. Alliancebernstein L.P. lifted its position in shares of Envista by 34.0% in the second quarter. Alliancebernstein L.P. now owns 6,098,445 shares of the company’s stock worth $119,164,000 after purchasing an additional 1,547,656 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in shares of Envista by 341.5% in the first quarter. Arrowstreet Capital Limited Partnership now owns 2,858,293 shares of the company’s stock worth $72,515,000 after purchasing an additional 2,210,847 shares in the last quarter. Quantinno Capital Management LP boosted its holdings in shares of Envista by 38.8% during the first quarter. Quantinno Capital Management LP now owns 2,694,970 shares of the company’s stock worth $68,371,000 after purchasing an additional 753,474 shares during the period. Finally, Millennium Management LLC boosted its holdings in shares of Envista by 1,442.7% during the fourth quarter. Millennium Management LLC now owns 2,420,615 shares of the company’s stock worth $52,552,000 after purchasing an additional 2,263,712 shares during the period.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.